EverydayHealthLogo
Dr. Jonathan Berek, MD

Dr. Jonathan Berek, MD

Stanford, CA

Accepting patients

Affiliated with a Castle Connolly Top Hospital

    Who is Dr. Berek, Gynecologic Oncologist in Stanford, CA?

    Dr. Jonathan Berek, MD is a Gynecologic Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified by the American Board of Obstetrics and Gynecology. Dr. Berek completed his residency at Harvard Medical School Brigham and Women's Hospital. Dr. Berek is fluent in English and Spanish, and is currently seeing new patients. Dr. Berek’s practice accepts Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Berek’s office at (650) 723-4000.

    What are Areas of Expertise for Dr. Berek?

    Dr. Jonathan Berek, MD is a highly-rated, board-certified Gynecologic Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Berek empowers patients to confidently navigate their health journey, specializing in Cervical Cancer, Gestational Trophoblastic Disease, Ovarian Cancer, Uterine Cancer, Vulvar & Vaginal Cancer, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Berek is dedicated to enhancing lives through expert, patient-centered care.

    Where did Dr. Berek go to medical school and complete their residency?

    • Fellowship: UCLA

    • Residency: Harvard Medical School Brigham and Women's Hospital

    Is Dr. Berek board certified in Gynecologic Oncologist?

    Yes, Dr. Jonathan Berek, MD is board certified by the American Board of Obstetrics and Gynecology , American Board of Obstetrics and Gynecology since 1983

    What languages does Dr. Berek speak?

    Dr. Berek and their clinical team can communicate with patients in the following languages:

    • English

    • Spanish

    What conditions does Dr. Berek treat?

    As a Gynecologic Oncologist, Dr. Berek diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Berek. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.

    Also known as:

    • Ovarian Cancer
    • Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
    • Cancer of the ovary
    • Ovarian carcinoma
    • Female reproductive cancer

    ICD-10 Codes:

    • C569: Malignant neoplasm of unspecified ovary

    Which procedures does Dr. Berek perform as a Gynecologic Oncologist?

    As a Gynecologic Oncologist, procedures performed by a Dr. Jonathan Berek may include:

    For detailed information, please contact Dr. Berek's office.

    Does Dr. Berek accept my insurance?

    Dr. Berek accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.

    What insurance plans does Dr. Berek accept in Stanford, CA?

    Dr. Berek in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.

    Top Insurances

    • All Other Third Party

    • Blue Shield of California

    • CVS Health (formerly Aetna)

    • Medicare

    • UnitedHealthcare

    View All Insurances

    Where is Dr. Berek's office located?

    Dr. Jonathan Berek's Primary Practice

    300 Pasteur Dr

    Stanford, CA 94305

    (650) 723-4000

    Get Directions

    Dr. Jonathan Berek's Practice 2

    900 Blake Wilbur Dr Fl MC5854

    Palo Alto, CA 94304

    Get Directions

    Recognitions

    Publications

    Abagovomab As Maintence Therapy in Patients With Epithelial Ovarian Cancer

    JOURL OF CLINICAL ONCOLOGY, 2013

    Cancer of the ovary, fallopian tube, and peritoneum

    INTERTIOL JOURL OF GYNECOLOGY & OBSTETRICS, 2012

    FOXO3 siglling links ATM to the p53 apoptotic pathway following D damage

    TURE COMMUNICATIONS, 2012

    Current Magement of Vulvar Cancer

    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012

    Persolizing CA125 Levels for Ovarian Cancer Screening

    CANCER PREVENTION RESEARCH, 2011

    Strategies and Goals

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2010

    Survival After Second

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2009

    Oregovomab Maintence Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

    JOURL OF CLINICAL ONCOLOGY, 2009

    Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid

    AMERICAN JOURL OF OBSTETRICS AND GYNECOLOGY, 2008

    Trends in demographic and clinical characteristics in women

    AMERICAN JOURL OF OBSTETRICS AND GYNECOLOGY, 2008

    CA125 velocity at relapse is a highly significant predictor of survival post relapse

    JOURL OF IMMUNOTHERAPY, 2008

    Vulvar melanoma - A multivariable alysis of 644 patients

    OBSTETRICS AND GYNECOLOGY, 2007

    Impact of the human papilloma vaccine on cervical cancer

    JOURL OF CLINICAL ONCOLOGY, 2007

    The potential therapeutic role of lymph node resection in epithelial ovarian cancer

    BRITISH JOURL OF CANCER, 2007

    Elective oophorectomy for benign gynecological disorders

    MENOPAUSE-THE JOURL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007

    Prognostic factors responsible for survival in sex cord stromal tumors of the ovary

    GYNECOLOGIC ONCOLOGY, 2007

    Ovarian cancer in younger vs older women: a population-based alysis

    BRITISH JOURL OF CANCER, 2006

    Progress in ovarian cancer research

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2006

    An alysis of surgical versus chemotherapeutic intervention

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2006

    Pelvic exenteration for recurrent gynecologic maligncy

    GYNECOLOGIC ONCOLOGY, 2005

    Design, conduct and evaluation of a communication course for oncology fellows

    JOURL OF CANCER EDUCATION, 2005

    Lower uriry tract reconstruction with ileum in. the treatment of gynecologic maligncies

    GYNECOLOGIC ONCOLOGY, 2005

    Monoclol antibody therapy of ovarian cancer

    EXPERT REVIEW OF ANTICANCER THERAPY, 2005

    Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in

    JOURL OF CLINICAL ONCOLOGY, 2004

    Using fresh tissue dissection to teach human atomy in the clinical years

    ACADEMIC MEDICINE, 2004

    Current research and treatment for epithelial ovarian cancer

    EUROPEAN JOURL OF CANCER, 2003

    Cervical cancer: An opportunity to prevent and cure

    CANCER JOURL, 2003

    Progress in the magement of gynecologic cancer: consensus summary statement.

    Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C.

    Biologic and immunologic therapies for ovarian cancer.

    Jourl of clinical oncology, 2003

    Surgical resection of solitary brain metastasis from cervical cancer

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2003

    The use of continuous infusion topotecan in persistent and recurrent ovarian cancer

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2003

    CA125 levels are a weak predictor of optimal cytoreductive surgery

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2003

    Simplification of the new Bethesda 2001 classification System

    AMERICAN JOURL OF OBSTETRICS AND GYNECOLOGY, 2003

    FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 2002

    Advances in the magement of epithelial ovarian cancer

    JOURL OF REPRODUCTIVE MEDICINE, 2001

    A radical debulking of leiomyomatosis peritonealis dissemita from a colonic obstruction

    JOURL OF THE AMERICAN COLLEGE OF SURGEONS, 2000

    Ovarian cancer: Epidemiology, biology, and prognostic factors

    SEMIRS IN SURGICAL ONCOLOGY, 2000

    Concurrent chemotherapy

    JOURL OF CLINICAL ONCOLOGY, 2000

    Fraud. What is the evidence?

    Care magement jourls : Jourl of case magement ; The jourl of long term, 2000

    IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites

    JOURL OF IMMUNOLOGY, 1999

    Intraperitoneal alpha-interferon alterting with cisplatin in residual ovarian carcinoma

    GYNECOLOGIC ONCOLOGY, 1999

    Combition of transforming growth factor beta antisense

    GYNECOLOGIC ONCOLOGY, 1998

    Gene therapy for ovarian cancer: Development of novel treatment strategies

    INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 1997

    Complete debulking of epithelial ovarian cancer.

    cancer jourl from Scientific American, 1996

    Mixed mesodermal sarcoma of the ovary in a young patient

    EUROPEAN JOURL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996

    Evidence for a unifocal origin in familial ovarian cancer

    Gallion, H. H., Guarino, D., DePriest, P. D., VANGELL, J. R., Vaccarel, 1996

    RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER

    INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995

    ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN

    JOURL OF CLINICAL ONCOLOGY, 1995

    INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE

    NEW ENGLAND JOURL OF MEDICINE, 1995

    Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial Intertiol

    Intertiol jourl of gynecological cancer : official jourl of the Intert, 1995

    A MULTICENTER STUDY OF LAPAROSCOPIC MAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL

    JOURL OF THE AMERICAN COLLEGE OF SURGEONS, 1994

    PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNT OVARIAN EPITHELIAL NEOPLASMS

    OBSTETRICS AND GYNECOLOGY, 1994

    Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts

    Obstetrics and gynecology, 1994

    SURGICAL-MAGEMENT OF OVARIAN-CANCER

    SEMIRS IN SURGICAL ONCOLOGY, 1994

    MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER

    JOURL OF REPRODUCTIVE MEDICINE, 1994

    LAPAROSCOPIC MAGEMENT OF THE ADNEXAL MASS

    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 1994

    Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal

    Intertiol jourl of gynecological cancer : official jourl of the Intert, 1994

    Magement of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy

    The Jourl of the American Association of Gynecologic Laparoscopists, 1994

    Fine-needle aspiration cytology in the magement of gynecologic oncology patients.

    Cancer treatment and research, 1994

    PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMERCHAL FEMALE

    GYNECOLOGIC ONCOLOGY, 1993

    Current magement of invasive squamous carcinoma of the vulva.

    Clinics in geriatric medicine, 1993

    ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS

    ANLS OF ONCOLOGY, 1993

    Advanced ovarian cancer. Tumour markers.

    Anls of oncology, 1993

    PRESENCE OF INTERLEUKIN 10

    CYTOKINE, 1992

    INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON

    EUROPEAN JOURL OF CANCER, 1992

    STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1

    AMERICAN JOURL OF OBSTETRICS AND GYNECOLOGY, 1992

    2ND-LOOK VERSUS 2ND TURE

    GYNECOLOGIC ONCOLOGY, 1992

    ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMIL-PAIN IN POSTMENOPAUSAL WOMEN

    AMERICAN SURGEON, 1991

    ASSESSMENT OF CURRENT INTERTIOL FEDERATION OF GYNECOLOGY AND OBSTETRICS

    Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., J, 1991

    Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer

    JOURNAL OF CLINICAL ONCOLOGY, 2013

    Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses'

    Obstetrics and gynecology, 2013

    Cancer of the ovary, fallopian tube, and peritoneum

    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2012

    FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage

    NATURE COMMUNICATIONS, 2012

    Current Management of Vulvar Cancer

    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012

    Personalizing CA125 Levels for Ovarian Cancer Screening

    CANCER PREVENTION RESEARCH, 2011

    Strategies and Goals

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010

    Prophylactic and Risk-Reducing Bilateral Salpingo

    OBSTETRICS AND GYNECOLOGY, 2010

    Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?

    Berek, J. S., 2009

    Ovarian Conservation at the Time of Hysterectomy

    OBSTETRICS AND GYNECOLOGY, 2009

    Survival After Second

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009

    Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

    JOURNAL OF CLINICAL ONCOLOGY, 2009

    HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review

    GYNECOLOGIC ONCOLOGY, 2008

    Opportunities and challenges in ovarian cancer research

    GYNECOLOGIC ONCOLOGY, 2008

    Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid

    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008

    Trends in demographic and clinical characteristics in women diagnosed with corpus cancer

    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008

    CA125 velocity at relapse is a highly significant predictor of survival post relapse

    JOURNAL OF IMMUNOTHERAPY, 2008

    Elective oophorectomy in the gynecological patient: when is it desirable?

    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007

    Vulvar melanoma - A multivariable analysis of 644 patients

    OBSTETRICS AND GYNECOLOGY, 2007

    Impact of the human papilloma vaccine on cervical cancer

    JOURNAL OF CLINICAL ONCOLOGY, 2007

    The potential therapeutic role of lymph node resection in epithelial ovarian cancer

    BRITISH JOURNAL OF CANCER, 2007

    Lymphadenectomy in endometrioid uterine cancer staging

    CANCER, 2007

    Influence of the gynecologic oncologist on the survival of ovarian cancer patients

    OBSTETRICS AND GYNECOLOGY, 2007

    Ovarian conservation at the time of hysterectomy for benign disease

    CLINICAL OBSTETRICS AND GYNECOLOGY, 2007

    Elective oophorectomy for benign gynecological disorders

    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007

    Prognostic factors for uterine cancer in reproductive-aged women

    OBSTETRICS AND GYNECOLOGY, 2007

    CA125: Megadaltons of novel opportunities

    GYNECOLOGIC ONCOLOGY, 2007

    Prognostic factors responsible for survival in sex cord stromal tumors of the ovary

    GYNECOLOGIC ONCOLOGY, 2007

    Association of lymphadenectomy and survival in stage I ovarian cancer patients

    OBSTETRICS AND GYNECOLOGY, 2007

    The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma

    GYNECOLOGIC ONCOLOGY, 2006

    Ovarian cancer in younger vs older women: a population-based analysis

    BRITISH JOURNAL OF CANCER, 2006

    Response to commentaries on retention of the ovaries and long-term survival after hysterectomy

    CLIMACTERIC, 2006

    Patterns and progress in ovarian cancer over 14 years

    OBSTETRICS AND GYNECOLOGY, 2006

    Intraperitoneal chemotherapy for ovarian cancer

    CURRENT OPINION IN ONCOLOGY, 2006

    Surgery for ovarian cancer: how to improve survival

    LANCET, 2006

    10th Biennial Helene Harris Memorial Trust Meeting

    CANCER RESEARCH, 2006

    Progress in ovarian cancer research

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006

    An analysis of surgical versus chemotherapeutic intervention

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006

    Pelvic exenteration for recurrent gynecologic malignancy

    GYNECOLOGIC ONCOLOGY, 2005

    Design, conduct and evaluation of a communication course for oncology fellows

    JOURNAL OF CANCER EDUCATION, 2005

    Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies

    GYNECOLOGIC ONCOLOGY, 2005

    Rethinking the use of radiation and chemotherapy after radical hysterectomy

    GYNECOLOGIC ONCOLOGY, 2005

    Monoclonal antibody therapy of ovarian cancer

    EXPERT REVIEW OF ANTICANCER THERAPY, 2005

    Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix

    GYNECOLOGIC ONCOLOGY, 2005

    Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in

    JOURNAL OF CLINICAL ONCOLOGY, 2004

    Using fresh tissue dissection to teach human anatomy in the clinical years

    ACADEMIC MEDICINE, 2004

    Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004

    Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy

    CLINICAL CANCER RESEARCH, 2004

    Lymphovascular and perineural invasion in the parametria

    OBSTETRICS AND GYNECOLOGY, 2003

    Current research and treatment for epithelial ovarian cancer

    EUROPEAN JOURNAL OF CANCER, 2003

    Cervical cancer: An opportunity to prevent and cure

    CANCER JOURNAL, 2003

    Amifostine pretreatment for protection against topotecan-induced hematologic toxicity

    GYNECOLOGIC ONCOLOGY, 2003

    Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix

    GYNECOLOGIC ONCOLOGY, 2003

    Progress in the management of gynecologic cancer: consensus summary statement.

    Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C.

    Biologic and immunologic therapies for ovarian cancer.

    Journal of clinical oncology, 2003

    Surgical resection of solitary brain metastasis from cervical cancer

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003

    The use of continuous infusion topotecan in persistent and recurrent ovarian cancer

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003

    CA125 levels are a weak predictor of optimal cytoreductive surgery

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003

    Simplification of the new Bethesda 2001 classification System

    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003

    Specific keynote: Immunological therapy for ovarian cancer

    GYNECOLOGIC ONCOLOGY, 2003

    FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2002

    Advances in the management of epithelial ovarian cancer

    JOURNAL OF REPRODUCTIVE MEDICINE, 2001

    A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction

    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000

    Interferon plus chemotherapy for primary treatment of ovarian cancer

    LANCET, 2000

    [Epithelial ovarian cancer (advanced stage): consensus conference (1998)].

    Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J.

    Ovarian cancer: Epidemiology, biology, and prognostic factors

    SEMINARS IN SURGICAL ONCOLOGY, 2000

    Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125

    GYNECOLOGIC ONCOLOGY, 2000

    Concurrent chemotherapy

    JOURNAL OF CLINICAL ONCOLOGY, 2000

    Fraud. What is the evidence?

    Care management journals : Journal of case management ; The journal of, 2000

    IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites

    JOURNAL OF IMMUNOLOGY, 1999

    Endometrial cancer: Recent developments in evaluation and treatment

    ONCOLOGY-NEW YORK, 1999

    Recurrent mature cystic teratoma presenting as a perihepatic mass

    OBSTETRICS AND GYNECOLOGY, 1999

    Intraperitoneal interferon-alpha in residual ovarian carcinoma

    GYNECOLOGIC ONCOLOGY, 1999

    Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma

    GYNECOLOGIC ONCOLOGY, 1999

    Advanced epithelial ovarian cancer: 1998 consensus statements

    Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., 1999

    Basic research: how much do we know

    HAMILTON, T. C., Berek, J. S., Kaye, S. B., 1999

    Surgery during chemotherapy and at relapse of ovarian cancer

    Berek, J. S., Trope, C., Vergote, I., 1999

    A phase II study of intraperitoneal cisplatin

    GYNECOLOGIC ONCOLOGY, 1998

    Combination of transforming growth factor beta antisense

    GYNECOLOGIC ONCOLOGY, 1998

    Psammocarcinoma with an aggressive course

    OBSTETRICS AND GYNECOLOGY, 1998

    Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a r

    MEDICAL CARE, 1998

    Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer.

    Cancer treatment and research, 1998

    Progress in ovarian cancer

    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1998

    Gene therapy for ovarian cancer: Development of novel treatment strategies

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997

    Dysgerminoma: The role of conservative surgery

    GYNECOLOGIC ONCOLOGY, 1996

    Complete debulking of epithelial ovarian cancer.

    cancer journal from Scientific American, 1996

    Mixed mesodermal sarcoma of the ovary in a young patient

    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996

    Evidence for a unifocal origin in familial ovarian cancer

    Gallion, H. H., Guarino, D., DePriest, P. D., VANNAGELL, J. R., Vaccar, 1996

    Vascular endothelial growth factor expression is not regulated

    GYNECOLOGIC ONCOLOGY, 1996

    OVARIAN-CANCER SCREENING

    Berek, J. S., Bast, R. C., 1995

    RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995

    OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME

    LANCET, 1995

    ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN

    JOURNAL OF CLINICAL ONCOLOGY, 1995

    INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE

    NEW ENGLAND JOURNAL OF MEDICINE, 1995

    INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN

    GYNECOLOGIC ONCOLOGY, 1995

    Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International

    International journal of gynecological cancer : official journal of th, 1995

    A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES

    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1994

    PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS

    OBSTETRICS AND GYNECOLOGY, 1994

    THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION

    GYNECOLOGIC ONCOLOGY, 1994

    Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts

    Obstetrics and gynecology, 1994

    Advances in the biology of gynecologic cancer.

    Current opinion in oncology, 1994

    SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH

    GYNECOLOGIC ONCOLOGY, 1994

    SURGICAL-MANAGEMENT OF OVARIAN-CANCER

    SEMINARS IN SURGICAL ONCOLOGY, 1994

    MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER

    JOURNAL OF REPRODUCTIVE MEDICINE, 1994

    CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS -

    Gotlieb, W. H., Watson, J. M., Rezai, A., Johnson, M., MARTINEZMAZA, O, 1994

    CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA

    GYNECOLOGIC ONCOLOGY, 1994

    THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY

    Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasma, 1994

    LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS

    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 1994

    UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA

    OBSTETRICS AND GYNECOLOGY, 1994

    Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal

    International journal of gynecological cancer : official journal of th, 1994

    Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy

    The Journal of the American Association of Gynecologic Laparoscopists, 1994

    Fine-needle aspiration cytology in the management of gynecologic oncology patients.

    Cancer treatment and research, 1994

    CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY

    EXPERIMENTAL CELL RESEARCH, 1993

    PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA

    GYNECOLOGIC ONCOLOGY, 1993

    IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS

    Herbst, A. L., Berek, J. S., 1993

    GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES

    GYNECOLOGIC ONCOLOGY, 1993

    SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN

    GYNECOLOGIC ONCOLOGY, 1993

    PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE

    GYNECOLOGIC ONCOLOGY, 1993

    SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR

    GYNECOLOGIC ONCOLOGY, 1993

    Current management of invasive squamous carcinoma of the vulva.

    Clinics in geriatric medicine, 1993

    MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER

    Berek, J. S., MARTINEZMAZA, O., Hamilton, T., Trope, C., Kaern, J., Ba, 1993

    ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS

    ANNALS OF ONCOLOGY, 1993

    Advanced ovarian cancer. Tumour markers.

    Annals of oncology, 1993

    PRESENCE OF INTERLEUKIN 10

    CYTOKINE, 1992

    BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER

    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992

    INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON

    EUROPEAN JOURNAL OF CANCER, 1992

    CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN

    GYNECOLOGIC ONCOLOGY, 1992

    IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS

    MEDICAL CARE, 1992

    STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1

    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992

    EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX

    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1992

    2ND-LOOK VERSUS 2ND NATURE

    GYNECOLOGIC ONCOLOGY, 1992

    Interleukin 6 and cancer treatment.

    In vivo, 1991

    CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION

    Berek, J. S., HEAPS, J. M., Fu, Y. S., Juillard, G. J., Hacker, N. F., 1991

    ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN

    AMERICAN SURGEON, 1991

    ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR

    Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., J, 1991

    SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER

    Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., MARTIN, 1991

    A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA

    GYNECOLOGIC ONCOLOGY, 1991

    FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS

    GYNECOLOGIC ONCOLOGY, 1991

    What is Dr. Berek's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.

    Dr. Berek's National Provider Identifier (NPI) number is 1164447900.

    What common questions do patients ask about Dr. Berek?

    Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Berek

    What is Dr. Jonathan Berek's specialty?

    Dr. Berek is a Gynecologic Oncologist near Stanford, CA. An obstetrician/gynecologist specializing in gynecologic oncology provides consultation and comprehensive management for patients with gynecologic cancer. This includes performing diagnostic and therapeutic procedures essential for the total care of patients with gynecologic cancer and addressing any resulting complications. Contact Dr. Berek to book an appointment today.

    Is this Dr. Jonathan Berek affiliated with a ranked Castle Connolly Top Hospital?

    Yes, Dr. Berek is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals

    Where can I learn more about Gynecologic Oncologist?

    Explore Gynecologic Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.

    Is Jonathan Berek accepting new patients in Stanford, CA?

    Yes, Dr. Jonathan Berek is accepting new patients at this time.

    Does Dr. Jonathan Berek offer online booking?

    Please contact Dr. Berek's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.

    How can I make an appointment with Jonathan Berek?

    Please contact Dr. Berek's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.

    Which board certifications does Dr. Jonathan Berek have?

    Dr. Jonathan Berek is certified by the American Board of Obstetrics and Gynecology.

    Other Gynecologic Oncologist Near Stanford, CA

    TG

    Gynecologic Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    Dr. Oliver Dorigo, MD, PHD

    Gynecologic Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    EM

    Gynecologic Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    See All Specialists

    Doctors by Category

    Specialists